From L-R: Scion Life Sciences co-founders Aaron Kantoff, Tadd Wessel and Samuel Hall
A new VC fund emerges with $310M to create independent, commercial biotechs
A trio of former investors from OrbiMed, Apple Tree Partners and Medicxi has come together to form a new biotech fund called Scion Life Sciences …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
